Abstract: Provided is a pharmaceutical formulation with reduced particle formation, comprising an anti-coagulation factor IXa/X antibody (bispecific monoclonal antibody) that substitutes for coagulation factor VIII, or an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. Provided is a pharmaceutical formulation comprising an aqueous solution comprising a polyoxyethylene polyoxypropylene glycol (poloxamer), wherein the poloxamer is represented by formula I: HO(C2H4O)a(C3H6O)b(C2H4O)cH??(I) wherein a and c are independently an integer selected from 75 to 85; b is an integer selected from 22 to 33; and a, b and c are average values over the entire poloxamer, and, the poloxamer comprises poloxamer molecules comprising 34 or more (C3H6O) in the molecule at a ratio of 3% (w/w) or more of the total poloxamer.

Abstract: A gas spring has a single bypass across the piston that is controlled by a valve member of an elastomeric material, which restricts flow through the bypass when the gas spring is compressed (piston rod moving into the cylinder) and produces a pressure differential across the piston that varies inversely with temperature. The increasing force opposing compression of the gas spring due to the pressure differential across the bypass as the temperature of the gas spring, and thus the output force, decreases maintains the handle load more even over a range of temperatures. The elastomeric valve member has very little effect on the normal operation of the gas spring in the extension (rod moving out) mode.